NFKB1 and B-cell chronic lymphocytic leukemia: Nevertheless, previous studies have shown that ibrutinib not only inhibits BCR and nuclear factor kappa B (NF-κB) signaling (17–19) but also plays multiple roles in regulating the tumor microenvironment and T-cell immunity in CLL patients (20–22).